Basic Science Award recipient Alberto Ouro, PhD, presented his team’s cross-sectional study at the American Headache Society 68th Annual Scientific Meeting in Orlando, FL. The award recognizes the top basic...
A 1-year interim analysis of a phase 3, multicenter, open-label, 156-week extension study found overall reductions in systolic and diastolic blood pressure with atogepant 60 mg once daily in persons with...
In an Early Career Lecture Award study presented at the American Headache Society 68th Annual Scientific Meeting, nitroglycerin provoked headache and vestibular symptoms in participants with definite...
At the 2026 American Academy of Neurology Annual Meeting in Chicago, IL, investigators presented real-world evidence evaluating whether glucagon-like peptide-1 receptor agonists influence healthcare...
Several sessions at the 2026 American Association of Nurse Practitioners National Conference in Las Vegas, NV, will address migraine-related diagnosis, treatment, red flags, and care considerations across...
Recent studies in children and adults associate long COVID with worsened academic performance, attention difficulties, subjective cognitive impairment, and persistent neurologic and psychiatric symptoms.
...
The FDA has approved Avlayah (tividenofusp alfa-eknm) for certain pediatric patients with Hunter syndrome, marking the first approval targeting the disease's neurologic complications and offering clinicians...
The results from a recent randomized controlled trial showed that ultrasound-guided sphenopalatine ganglion (SPG) and greater occipital nerve blocks are equally effective in reducing headache frequency,...
In a recent study, exposure to fine particulate matter (PM2.5) was associated with both more advanced Alzheimer disease neuropathologic change and greater dementia severity, with much of this link mediated...
